Advanced Circulatory Systems out of Roseville, Minnesota has announced promising results from a clinical trial of its ResQCPR System, which combines the firm’s ResQPump active compression-decompression CPR device and ResQPOD impedance threshold device. 
Supported by the National Institute of Health, the study compared CPR performed with the device combination against traditional CPR and found that the new method offers improved protection to the heart and brain following cardiac arrest.
Dubbed the ResQTrial, the trial also investigated the use of therapeutic hypothermia in conjunction with the ResQCPR System. When compared to standard CPR performed with therapeutic hypothermia, the ResQCPR System led to a six-fold increase in patients who improved from poor neurologic function at hospital discharge to good neurologic function after 90 days. “These findings provide a new way to significantly decrease the number of patients with poor long-term neurological function, especially when the ResQCPR System is applied early during cardiac arrest,” explained Dr. Marvin Wayne, principal author of the study in a press release.
The trial involved more than 5,000 patients based at seven sites located throughout the United States.
Earlier, Advanced Circulatory System had shown that the ResQCPR System triples blood flow to the heart and brain when used early to treat cardiac arrest. Primary results from the ResQTrial found that the device combination could improve long-term cardiac arrest survival rates.
More from the press release: NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
Study info: The ResQ Trial
Flashbacks: Lancet Study Shows Device Augmented CPR May Improve Survival; ResQPOD Circulatory Enhancer